Multiplikator Forward P/S: Accuray Incorporated (ARAY)
Accuray Incorporated (ARAY) is implementing AI algorithms for adaptive therapy, stimulating demand. The company's expected P/S ratio reflects the price action, with the indicator currently standing at 0.00. Revenues are based on software and service maintenance, despite the high cost of producing accelerators. Meanwhile, fierce competition for clinic budgets and the risk of technological obsolescence are putting pressure on the issuer's market position.
Rincian metrik lan analitis perusahaan Accuray, Inc. (ARAY)
- rega saiki lan proyeksi nilai saham:
- indikator kapitalisasi bursa perusahaan:
- statistik nilai buku emiten:
- data tingkat utang lan likuiditas finansial:
Total Utang marang Modal Accuray Incorporated|ARAY - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Accuray Incorporated|ARAY - Utang kumulatif perusahaan|Utang marang nilai buku Accuray, Inc.|ARAY - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Accuray Incorporated|Likuiditas cepet accuray.com
- indikator pendapatan resik lan kelipatan nilai:
ARAY - Bathi perusahaan|Proyeksi bathi mangsa ngarep Accuray Incorporated|ARAY - Koefisien rega marang bathi|Rega marang bathi mangsa ngarep Accuray Inc.|ARAY - Rega marang bathi kanthi panyesuaian wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Accuray, Inc.|ARAY - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Accuray Incorporated|ARAY - Bathi saben siji saham sajrone 12 wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan accuray.com|ARAY - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Accuray Incorporated
- data total pendapatan lan volume dodolan:
Analisis wiwitan perusahaan:Accuray (ARAY)
This indicator determines the market value of Accuray Incorporated (ARAY) relative to expected sales volume, allowing for an assessment of the degree of optimism priced in or the risk of overpayment. By analyzing the forward revenue multiple, an investor can see the stability of the capitalization of Accuray Incorporated (ARAY), which is supported by the patent protection of robotic radiation systems and the complexity of integrating equipment into medical infrastructure.
Pesaing wigati
Multiplikator Forward P/S ONC (BeiGene)|HALO - Multiplikator forward rega marang pendapatan|RevMed - Multiplikator Forward P/S|Ascentage Pharma Corp (AAPG) - Multiplikator forward rega marang pendapatan|CGON (CG Oncology, Inc.) - Multiplikator forward rega marang pendapatan|urogen.com (URGN) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Bicara Therapeutics|PSNL: Rega forward marang dodolan|Multiplikator Forward P/S ERAS|Multiplikator Forward P/S Delcath Corp (DCTH)|Y-mAbs Therapeutics - Multiplikator forward rega marang pendapatan|aurabiosciences.com (AURA) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|CADL: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan SLS (SELLAS Life Sciences)|ACTU: Multiplikator Forward P/S|CTOR - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan TuHURA Biosciences Inc.|Kapitalisasi marang prakiraan pendapatan TARA (protaratx.com)|Multiplikator Forward P/S FATE|Multiplikator forward rega marang pendapatan aadibio.com WHWK|Rasio rega marang prakiraan pendapatan TScan Therapeutics, Inc. TCRX|Champions Oncology Inc (CSBR) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|XBIT - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan CVM (CEL-SCI Corporation)|OS Therapies (OSTX) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan RADX (radiopharmtheranostics.com)|Rasio rega marang prakiraan pendapatan Artiva Biotherapeutics Inc.|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Adlai Nortye Limited ANL|Rasio rega marang prakiraan pendapatan Veru Inc. (VERU)|TPST (tempesttx.com) - Rega forward marang dodolan|Multiplikator Forward P/S XLO (Xilio Therapeutics)|Multiplikator Forward P/S Renovaro Biosciences RENB|MURA: Multiplikator forward rega marang pendapatan|Kairos Pharma Ltd - Rasio rega marang pendapatan sing dikarepake|OKUR: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep CytoMed Therapeutics Limited (GDTC)|CRIS (Curis Inc.) - Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan APLM (Apollomics Corp)|Multiplikator Forward P/S THAR|Multiplikator Forward P/S advanbiomed.com (ADVB)|Rasio rega marang prakiraan pendapatan Genprex, Inc. GNPX|Rega forward marang dodolan CLDI|Sunshine Biopharma, Inc. - Multiplikator Forward P/S|XBIO - Multiplikator Forward P/S|SLRX (Salarius) - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Kitov Pharma (PPBT)|AONC (American Oncology Network Inc) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan beigene.com (BGNE)|Multiplikator Forward P/S CKPT|Multiplikator Forward P/S elevationoncology.com (ELEV)|Rasio rega marang prakiraan pendapatan iCAD ICAD|IKNA: Kapitalisasi marang prakiraan pendapatan|Notable Labs, Ltd. - Multiplikator Forward P/S|Viracta Therapeutics (VIRX) - Multiplikator forward rega marang pendapatan|MOR: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep NAYA Biosciences Inc (NAYA)|Rasio rega marang prakiraan pendapatan Ascentage Pharma Group Ltd
